ClinicalTrials.gg
CompletedNCT00249821SGA OPTIMISUpdated Sep 26, 2017Results posted

Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age

A Phase 3 interventional study of Saizen® and Saizen® in Small Gestational Age (SGA), sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-09-26.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Feb 2005, registered Nov 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Study summary

Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving 0.035 mg/kg/day (0.24 mg/kg/week) of Saizen® during 1 year after an initial 3-year treatment of recombinant human growth hormone (r-hGH) therapy with 0.057 mg/kg/day in both groups.

02

Conditions studied

  • Small Gestational Age (SGA)
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):

  • Written consent form signed by the parents / legal guardian, and child if possible
  • Subject born SGA and receiving a r-hGH therapy for this pathology
  • Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys
  • Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day
  • Height gain during the first 2 years of GH treatment > 1 SD compared with the initial value

Exclusion criteria

Exclusion Criteria:

To be eligible for inclusion in this study the subjects must not meet any of the following criteria:

  • Known to Somatropin or any of the
  • Active neoplasia (either newly diagnosed or recurrent)
  • Intracranial hypertension
  • Known diabetes mellitus
  • Proliferative or preproliferative diabetic retinopathy
  • Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion
  • Obesity defined as degree 1 on the corpulence curves
  • Precocious puberty
  • Pubertal status: Tanner breast development stage > 2 for girls, and testicular volume > 4 milliliter (mL) or testicular length > 3 centimeter (cm) and/or testosterone value >1 nanomole/liter [nmol/L] (0.29 gram/mL [g/mL]) for boys For girls > 9 years and Tanner breast development stage 1: uterine size > 35 millimeter (mm)
  • Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis
  • Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment
  • Participation to any clinical study within the 30 days preceding study entry
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Saizen® 0.057 mg/kg/day

    Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than \[\<\] -2 SDS or greater than \[\>\] -2 SDS)

    Drug: Saizen®

  • Experimental
    Saizen® 0.035 mg/kg/day

    Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (\< -2 SDS or \> -2 SDS)

    Drug: Saizen®

Interventions

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

    Also known as: somatropin

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.

    Also known as: somatropin

06

What researchers measure

Primary outcomes

  1. Height Velocity

    Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely: HV = {(h-hp)/(d-dp)} \* 365.25 \[centimeter (cm)/year\] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years. HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.

    Time frame: Month 12

Secondary outcomes

  1. Change From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12

    Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) \[age and sex-matched reference\]. Greater H-SDS indicates greater height.

    Time frame: Baseline (randomization), Month 6 and Month 12

  2. Height Velocity-Standard Deviation Score (HV-SDS)

    Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.

    Time frame: Month 6 and Month 12

  3. Change From Baseline in Height at Month 6

    Time frame: Baseline (randomization) and Month 6

  4. Change From Baseline in Bone Age at Month 12

    Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.

    Time frame: Baseline (randomization) and Month 12

  5. Insulin Like Growth Factor-1 (IGF-1) Levels

    Time frame: Baseline (randomization), Month 6 and Month 12

  6. Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels

    Time frame: Baseline (randomization), Month 6 and Month 12

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).

    Time frame: Baseline (randomization) until Month 12

07

Results

Posted Oct 10, 2012
Limitations and caveats
Participants' inclusion period was extended but due to remaining low recruitment rate, it was finally decided to stop enrollment even if only 22 participants were enrolled.

Participant flow

Participant flow — Overall Study
MilestoneSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Started1012
Completed1011
Not completed01
Withdrew: Technical problem01

Outcome measures

PrimaryHeight Velocity

Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely: HV = {(h-hp)/(d-dp)} \* 365.25 \[centimeter (cm)/year\] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years. HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.

Time frame:
Month 12
Reported as:
Mean · centimeter (cm)/year
Height Velocity
centimeter (cm)/yearSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Height Velocity6.40 ± 1.354.40 ± 1.15
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.001
SecondaryChange From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12

Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) \[age and sex-matched reference\]. Greater H-SDS indicates greater height.

Time frame:
Baseline (randomization), Month 6 and Month 12
Reported as:
Mean · standard deviation score
Change From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12
standard deviation scoreSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Baseline (randomization)-1.30 ± 0.42-1.50 ± 0.37
Change at Month 60.30 ± 0.220.10 ± 0.10
Change at Month 120.30 ± 0.30-0.10 ± 0.24
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.012
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.002
SecondaryHeight Velocity-Standard Deviation Score (HV-SDS)

Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.

Time frame:
Month 6 and Month 12
Reported as:
Mean · standard deviation score
Height Velocity-Standard Deviation Score (HV-SDS)
standard deviation scoreSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Month 6 (n= 10,11)0.60 ± 0.440.10 ± 0.22
Month 12 (n=10,12)0.30 ± 0.29-0.10 ± 0.24
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.022
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.002
SecondaryChange From Baseline in Height at Month 6
Time frame:
Baseline (randomization) and Month 6
Reported as:
Mean · cm
Change From Baseline in Height at Month 6
cmSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Baseline (randomization)121.10 ± 7.99119.20 ± 5.29
Change at Month 63.60 ± 1.312.50 ± 0.99
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.029
SecondaryChange From Baseline in Bone Age at Month 12

Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.

Time frame:
Baseline (randomization) and Month 12
Reported as:
Mean · years
Change From Baseline in Bone Age at Month 12
yearsSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Baseline (randomization) (n = 9,10)7.50 ± 0.827.00 ± 1.85
Change at Month 12 (n=9,7)1.40 ± 0.791.40 ± 0.89
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.972
SecondaryInsulin Like Growth Factor-1 (IGF-1) Levels
Time frame:
Baseline (randomization), Month 6 and Month 12
Reported as:
Mean · microgram/liter (mcg/L)
Insulin Like Growth Factor-1 (IGF-1) Levels
microgram/liter (mcg/L)Saizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Baseline (randomization) (n= 10,11)319.60 ± 146.27275.40 ± 98.82
Month 6 (n= 9,7)369.30 ± 120.13262.40 ± 65.52
Month 12 (n=10,10)414.30 ± 176.70263.00 ± 120.70
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.058
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.026
SecondaryInsulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels
Time frame:
Baseline (randomization), Month 6 and Month 12
Reported as:
Mean · milligram/L (mg/L)
Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels
milligram/L (mg/L)Saizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Baseline (randomization) (n= 10,10)3.40 ± 0.703.40 ± 0.60
Month 6 (n= 9,7)3.00 ± 0.843.30 ± 0.81
Month 12 (n= 9,10)3.60 ± 1.023.50 ± 0.77
Statistical analysis
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.793
  • Saizen® 0.057 mg/kg/Day vs Saizen® 0.035 mg/kg/Day · ANCOVA · p = 0.055
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).

Time frame:
Baseline (randomization) until Month 12
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
Number of Participants With Treatment Emergent Adverse Events (TEAEs)21

Adverse events

Collected over Adverse Events (AEs) are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until 4 weeks post drug administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saizen® 0.057 mg/kg/Day—0/10 (0%)2/10 (20%)
Saizen® 0.035 mg/kg/Day—0/12 (0%)1/12 (8.3%)
Most frequent other events
Most frequent other events
EventSaizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/Day
BronchitisInfections and infestations1/100/12
Ear infectionInfections and infestations1/100/12
Insulin-like growth factor increasedInvestigations1/100/12
AsthmaImmune system disorders0/101/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Saizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/DayTotal
Mean8.00 ± 1.497.90 ± 0.908.00 ± 1.17
Sex: Female, Male
Sex: Female, Male(Participants)Saizen® 0.057 mg/kg/DaySaizen® 0.035 mg/kg/DayTotal
Female448
Male6814
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Chatelain P, Colle M, Nako JP, Le Luyer B, Wagner K, Berlier P, Tauber M. Optimization of growth hormone dosing in children born small for gestational age: an open-label, randomized study of children during the fourth year of therapy. Horm Res Paediatr. 2012;77(3):156-63. doi: 10.1159/000337216. Epub 2012 Apr 12. PubMed 22508151 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2005 to primary completion in Sep 2007, 31 months.

Results were first posted in Oct 2012, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2005
First posted
Nov 7, 2005
StartActual
Feb 28, 2005
Primary completionActual
Sep 30, 2007
CompletionActual
Sep 30, 2007
Results first posted
Oct 10, 2012
Last update
Sep 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00249821
Collaborators
Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany
Responsible party
Sponsor
First posted
Nov 7, 2005
Start date
Feb 28, 2005
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Results posted
Oct 10, 2012
Last update
Sep 26, 2017

Study contacts

Medical Responsible
study director · Merck Serono S.A.S, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion